Mcmaster University

A McMaster University-led international study analyzed 93 randomized controlled trials involving over 11,000 participants to identify the most effective treatments for chronic hives.

Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.

McMaster University's inhaled COVID-19 vaccine demonstrated safety and immunogenicity in a Phase 1 trial of 36 healthy adults, with results published in Nature Communications.

The ACHIEVE trial, the largest study to date with 2,538 dialysis patients across 12 countries, found that spironolactone did not significantly reduce cardiovascular death or heart failure hospitalization compared to placebo.

The 62nd European Renal Association Congress in Vienna will present seven late-breaking clinical trials addressing chronic kidney disease, dialysis patients, and glomerular disease developments.

Late-breaking results from the CLEAR OASIS 9 trial reveal that colchicine failed to reduce cardiovascular events after myocardial infarction despite lowering inflammatory markers.

Researchers have identified lariocidin, the first new class of antibiotics to reach the market in nearly 30 years, discovered in bacteria from backyard soil samples.

Canadian researchers at McMaster University have begun phase-2 clinical trials for AeroVax, an innovative inhaled COVID-19 vaccine that directly targets the lungs and upper airways where infection begins.

A comprehensive 12-year PURE study across 17 countries shows significant underutilization of secondary prevention medications for cardiovascular disease, with usage rates dropping to 31.3% in the final study visit.